Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on the Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity

NCT06214195 is registered in ClinicalTrials.gov with Zhejiang Cancer Hospital as lead sponsor.

NCT NCT06214195
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06214195 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on the Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
Lead sponsor
Zhejiang Cancer Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
January 20, 2024
Completion date
December 1, 2030
Enrollment
276 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiotoxicity induced by drug therapy for breast cancer